Intangibles, Net

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles, net, consisted of the following:


	September 30, 2022
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(11,924)	$	1,616
Customer relationships	15 - 25	Accelerated	96,682		(94,866)		1,816
Currently marketed products	9 - 15	Straight-Line	275,700		(41,557)		234,143
Licenses	11 - 16	Straight-Line	85,800		(17,214)		68,586
Developed technology	9	Straight-Line	2,400		(610)		1,790
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,762	$	(166,171)	$	323,591


	December 31, 2021
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(11,510)	$	2,030
Customer relationships	15 - 25	Accelerated	96,880		(94,630)		2,250
Currently marketed product	9 - 15	Straight-Line	275,700		(23,345)		252,355
Licenses	11 - 16	Straight-Line	85,800		(11,555)		74,245
Developed technology	9	Straight-Line	2,400		(410)		1,990
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,960	$	(141,450)	$	348,510

The Company recorded amortization expense for its intangible assets of $8.3 million and $8.4 million for the three months ended September 30, 2022 and 2021, respectively, and $24.9 million and $19.1 million for the nine months ended September 30, 2022 and 2021, respectively.

In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:


(in thousands)	Amount
Remainder of 2022	$	8,310
2023	32,634
2024	32,563
2025	32,508
2026	32,497
2027 and thereafter	169,439
Total	$	307,951